Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013

Clinical Infectious Diseases

Volumn 61, Issue 12, 2015, Pages 1792-1799

  Payne, Daniel C ^a   Selvarangan, Rangaraj ^b   Azimi, Parvin H ^c   Boom, Julie A ^d,e   Englund, Janet A ^f   Staat, Mary Allen ^g   Halasa, Natasha B ^h   Weinberg, Geoffrey A ⁱ   Szilagyi, Peter G ^i,j   Chappell, James ^h   McNeal, Monica ^g   Klein, Eileen J ^f   Sahni, Leila C ^d   Johnston, Samantha H ^c   Harrison, Christopher J ^b   Baker, Carol J ^e   Bernstein, David I ^g   Moffatt, Mary E ^b   Tate, Jacqueline E ^a   Mijatovic Rustempasic, Slavica ^a   Esona, Mathew D ^a   Wikswo, Mary E ^a   Curns, Aaron T ^a   Sulemana, Iddrisu ^a   Bowen, Michael D ^a   Gentsch, Jon R ^a   Parashar, Umesh D ^a   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

acute gastroenteritis; rotavirus vaccine; RV1 Rotarix; RV5 RotaTeq; surveillance

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE; RIX4414 VACCINE; VIRUS ANTIGEN; VIRUS RNA;

ARTICLE; CHILD; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; GENOTYPE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; ROTAVIRUS GASTROENTERITIS; ROTAVIRUS INFECTION; UNITED STATES; VACCINATION; VIRUS STRAIN; EMERGENCY HEALTH SERVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL MONITORING; FECES; GASTROENTERITIS; GENETICS; IMMUNOLOGY; PRESCHOOL CHILD; ROTAVIRUS INFECTIONS; TREATMENT OUTCOME; VIROLOGY;

ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; EMERGENCY MEDICAL SERVICES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL MONITORING; FECES; FEMALE; GASTROENTERITIS; GENOTYPE; HOSPITALIZATION; HUMANS; INFANT; MALE; RNA, VIRAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME; UNITED STATES; VACCINES, ATTENUATED;

EID: 84961613407     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ872     Document Type: Article

References (26)

1. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
2. Linhares AC, Velázquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: A randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
3. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX 4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43.
4. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007; 370:1757-63.
5. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009; 58:1-26.
6. Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010; 29:1133-5.
7. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011; 128:e267-75.
8. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis 2013; 57:13-20.
9. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013; 132:e25-33.
10. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465-71.
11. Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30(1 suppl):S30-4.
12. CorteseMM,Tate JE, Simonsen L, et al.Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010; 29:489-94.
13. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011; 30(1 suppl):S56-60.
14. Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011; 53:245-53.
15. Payne DC, Staat MA, Edwards KM, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008; 122:1235-43.
16. Payne DC, Szilagyi P, Staat MA, et al. Secular variation in US rotavirus disease rates and serotypes-Implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J 2009; 28:948-53.
17. Hull JJ, Teel EN, Kerin TK, et al. United States rotavirus strain surveillance from 2005 to 2008. Pediatr Infect Dis J 2011; 30:S42-7.
18. Russka T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67.
19. Wikswo ME, Payne DC, Parashar UD. Validation of a modified Vesikari Score in US children with gastroenteritis. 11th International Rotavirus Symposium. New Delhi, September 2014.
20. World Health Organization. Handbook: IMCI Integrated Management of Childhood Illness. 2005:27-9. ISBN 92 4 154644 1.
21. Centers for Disease Control and Prevention. Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination: 2000-2014. MMWR 2015; 64:337-42.
22. Rahman M, Matthijnssens J, Yang X, et al. Evolutionary history and global spread of the emerging G12 human rotaviruses. J Virol 2007; 81:2382-90.
23. Mijatovic-Rustempasic S, Teel EN, Kerin TK, et al. Genetic analysis of G12P[8] rotaviruses detected in the largest US G12 genotype outbreak on record. Infect Genet Evolution 2014; 21:214-9.
24. Velazquez R, Calva JJ, Lourdes Guerrero M, et al. Cohort study of rotavirus serotype patterns in symptomatic and asymptomatic infections in Mexican children. Pediatr Infect Dis J 1993; 12:54-61.
25. Vesikari T, Karnoven A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: The Finnish Extension Study. Eur J Pediatr 2010; 169:1379-86.
26. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010; 125:e199-207.